Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.69 |
| ▸ | MAPK12 | P53778 | 18/20 | 0.69 |
| ▸ | HCK | P08631 | 16/20 | 0.69 |
| ▸ | TNF | P01375 | 2/20 | 0.69 |
| ▸ | SRC | P12931 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7844849 | 0.92 | MAPK14 (0.82) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL29593973 | 0.90 | MAPK14 (0.85) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL299715 | 0.90 | MAPK14 (0.85) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL6194444 | 0.87 | MAPK14 (0.73) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL6885519 | 0.86 | MAPK14 (0.74) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL6884581 | 0.84 | MAPK14 (0.66) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL6243534 | 0.83 | MAPK14 (0.83) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL295686 | 0.82 | MAPK14 (1.00) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL29593358 | 0.82 | MAPK14 (1.00) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL29593539 | 0.82 | MAPK14 (0.59) | MAPK14MAPK12HCKTNFSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023961-A1 | Aryl ureas with raf kinase and angiogenisis inhibiting activity | BAYER CORPORATION | 2004-02-05 | — | — | US | disclosed |
| WO-2003068223-A1 | ARYL UREAS WITH RAF KINASE AND ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023961-A1 | Aryl ureas with raf kinase and angiogenisis inhibiting activity | BRAF, FLT1, RAF1 | MAPK14 110/4885MAPK12 82/4885HCK 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.